Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2026-01-02 @ 7:26 PM
Study NCT ID:
NCT03801369
Status:
TERMINATED
Last Update Posted:
2025-11-21
First Post:
2019-01-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Sponsor:
Gordon Mills, MD, PhD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
STUDY00018504
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None